On Friday, Shares of Vale SA (ADR) (NYSE:VALE), lost -4.29% to $3.57.
Fabio Barbosa, who assisted Vale SA become the world’s second-largest mining company last decade as chief financial officer, died on Sunday. He was 54, according to Bloomberg
Barbosa was Vale’s CFO and head of investor relations from 2002 to 2010, the company said in a statement announcing his death. During Barbosa’s tenure, together with then-Chief Executive Officer Roger Agnelli, the Rio de Janeiro-based miner expanded operations and undertook the biggest foreign acquisition by a Brazilian company at the time with the purchase of Inco Ltd. in late 2006. The purchase, at a time of booming demand for minerals and metals, allowed Vale to multiply its market capitalization to more than $200 billion by 2008.
“Fabio was an excellent colleague, an extremely competent professional who has contributed in an invaluable manner to Vale’s development during the eight years he take partd in our executive board,” Chief Executive Officer Murilo Ferreira said in the statement. “It was with his experience and dedication that Vale achieved noteworthy results in its history. ” Bloomberg Report
Vale S.A. (NYSE:VALE) is a metals and mining company. The Company is also a producer of iron ore and iron ore pellets, and nickel. The Company also produces manganese ore, ferroalloys, metallurgical and thermal coal, copper, platinum group metals (PGMs), gold, silver, cobalt, potash, phosphates and other fertilizer nutrients.
Shares of Anavex Life Sciences Corp (NASDAQ:AVXL), inclined 8.70% to $6.00, during its last trading session.
On November 25, Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, declares that Kristina M. Capiak, CCRP has been promoted the Company’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, counting filings and interactions with the FDA and other regulatory authorities.
“We are excited to expand Ms. Capiak’s role to oversee the Company’s clinical development programs and other indications given Ms. Capiak’s expertise and we are delighted to have her on our team,” said Dr. Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex.
Ms. Capiak’s background also comprises clinical trial staffing and oversight for more than 60 clinical trials at both Columbia University Medical Center, where she co-authored several papers, and Memorial Sloan-Kettering Cancer Center, where she became a Certified Clinical Research Professional (CCRP) through the Society of Clinical Research Associates.
Anavex Life Sciences Corp (NASDAQ:AVXL), a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates comprise ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease.
Finally, American Eagle Outfitters (NYSE:AEO), ended its last trade with -0.43% loss, and closed at $16.40.
In conjunction with American Eagle Outfitters (AEO) third quarter 2015 earnings release, you are invited to listen to a broadcast of the conference call live over the Internet on Wednesday, December 2, 2015 at 4:15 p.m. ET.
What: American Eagle Outfitters Third Quarter 2015 Earnings Conference Call
When: 4:15 p.m. ET, Wednesday, December 2, 2015
American Eagle Outfitters (NYSE:AEO), is an apparel and accessories retailer. The Company offers clothing, accessories and personal care products. The Company operates under the American Eagle Outfitters and aerie by American Eagle Outfitters brands. The American Eagle Outfitters brand offers denims, pants, shorts, sweaters, fleece, outerwear, graphic t-shirts, footwear and accessories.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.